Percutaneous coronary intervention (PCI) with modern drug-eluting stents (DES) represents the most common interventional mode of treatment for acute and chronic coronary syndromes. Adjunctive pharmacotherapy with dual antiplatelet therapy (DAPT) consisting of aspirin plus a P2Y12 receptor inhibitor has substantially improved the short- and long-term procedural results toward better anti-ischemic protection by minimizing the risk of stent thrombosis, though at the cost of increased bleeding risk. A 6-month (m) and 12-m DAPT duration following DES implantation are the most commonly applied strategies in chronic and acute coronary syndromes, respectively. However, the significance of bleeding risk by longer DAPT duration has led to tailoring antiplatelet treatment by using novel DES that enable shorter antiplatelet protocols without compromising efficacy. The working hypothesis is that a thrombo-resistant DES with anti-inflammatory and rapid endothelialization properties will lead to rapid neointimal healing and, most likely, shorter DAPT duration.
Read full article: https://doi.org/10.1016/j.carrev.2020.03.026